Tiekun Yan

Results from part A of the multi-center, double-blind, randomized, placebo-controlled NefIgArd trial, which evaluated targeted-release formulation of budesonide for the treatment of primary immunoglobulin A nephropathy

Jonathan Barratt, Richard Lafayette, Jens Kristensen et al. · Kidney International · 2022 · 215 citations · Full text

Pharmacy, Nephrology, Pharmacotherapy +13

A pre-specified analysis of the Dapagliflozin and Prevention of Adverse Outcomes in Chronic Kidney Disease (DAPA-CKD) randomized controlled trial on the incidence of abrupt declines in kidney function

Hiddo J.L. Heerspink, David Z.I. Cherney, Douwe Postmus et al. · Kidney International · 2021 · 94 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17

Spironolactone promotes autophagy via inhibiting PI3K/AKT/mTOR signalling pathway and reduce adhesive capacity damage in podocytes under mechanical stress

Dong Li, Zhenyu Lu, Zhongwei Xu et al. · Bioscience Reports · 2016 · 66 citations · Full text

Medicine, Cell Biology, Pathobiology +17

Clinical Significance of Galactose-Deficient IgA1 by KM55 in Patients with IgA Nephropathy

Kai Zhang, Qiongqiong Li, Yaru Zhang et al. · Kidney & Blood Pressure Research · 2019 · 35 citations · Full text

Medicine, Nephrology, Pathology +17

Effects of febuxostat on delaying chronic kidney disease progression: a randomized trial in China

Hongtao Yang, Rong Li, Qing Li et al. · International Urology and Nephrology · 2022 · 25 citations

Medicine, Nephrology, Pharmacotherapy +14